At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jun 11, 2026 at 07:00 ET
C4 Therapeutics presented updated Phase 1 data for cemsidomide at EHA 2026, showing a 53% overall response rate at the 100 µg RP2D in heavily pretreated RRMM patients (median 7 prior lines). Responses deepened over time, with MRD negativity achieved in two patients. The data reinforce cemsidomide's differentiated safety profile and support its development as a potential best-in-class IKZF1/3 degrader, though the stock may have limited upside given prior data disclosures and the early-stage nature of the program.
- 53% ORR at 100 µg RP2D in heavily pretreated RRMM patients (median 7 prior lines)
- 75% of patients received prior BCMA therapy and prior CAR-T or T-cell engager therapy
- Responses deepened over time: one patient at 100 µg deepened from PR to sCR, another from PR to VGPR
- MRD negativity achieved in two patients at 100 µg who achieved sCR and CR
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access